New therapeutic targets in the management of urothelial carcinoma of the bladder

References

• PloegMAbenKKKiemeneyLAThe present and future burden of urinary bladder cancer in the worldWorld J Urol200927328929319219610
   PubMed Web of Science ®Google Scholar
• HerrHWTumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcomeJ Urol200016316061 discussion 61–6210604314
   PubMed Web of Science ®Google Scholar
• Millan-RodriguezFChechile-TonioloGSalvador-BayarriJPalouJAlgabaFVicente-RodriguezJPrimary superficial bladder cancer risk groups according to progression, mortality and recurrenceJ Urol20001643 Pt 168068410954628
   PubMed Web of Science ®Google Scholar
• SylvesterRJvan der MeijdenAPOosterlinckWPredicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trialsEur Urol2006493466475 discussion 475–47716442208
   PubMed Web of Science ®Google Scholar
• GrossmanHBNataleRBTangenCMNeoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancerN Engl J Med2003349985986612944571
   PubMed Web of Science ®Google Scholar
• SteinJPSkinnerDGRadical cystectomy for invasive bladder cancer: long-term results of a standard procedureWorld J Urol200624329630416518661
   PubMed Web of Science ®Google Scholar
• EfstathiouJASpiegelDYShipleyWULong-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experienceEur Urol201261470571122101114
   PubMed Web of Science ®Google Scholar
• SiegelRDeSantisCVirgoKCancer treatment and survivorship statistics, 2012CA Cancer J Clin201262422024122700443
   PubMed Web of Science ®Google Scholar
• FedeliUFedewaSAWardEMTreatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007J Urol20111851727821074192
   PubMed Web of Science ®Google Scholar
• DashAGalskyMDVickersAJImpact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladderCancer2006107350651316773629
   PubMed Web of Science ®Google Scholar
• SchragDMitraNXuFCystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare populationUrology20056561118112515922428
   PubMed Web of Science ®Google Scholar
• GrimmMOSteinhoffCSimonXSpiegelhalderPAckermannRVogeliTAEffect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational studyJ Urol20031702 Pt 143343712853793
   PubMed Web of Science ®Google Scholar
• DuttaSCSmithJAJrShappellSBCoffeyCSChangSSCook-sonMSClinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomyJ Urol2001166249049311458053
   PubMed Web of Science ®Google Scholar
• Bladder Cancer Version 2Jenkintown (PA)National Comprehensive Cancer Network (NCCN)2011Clinical Practice Guidelines in Oncology, Version 2. 2012 Available from: http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdfAccessed July 18, 2012
   Google Scholar
• BabjukMOosterlinckWSylvesterREuropean Association of Urology (EAU)EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 updateEur Urol2011596997100821458150
   PubMed Web of Science ®Google Scholar
• HallMCChangSSDalbagniGGuideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 updateJ Urol200717862314233017993339
   PubMed Web of Science ®Google Scholar
• O’DonnellMAAdvances in the management of superficial bladder cancerSemin Oncol2007342859717382792
   PubMed Web of Science ®Google Scholar
• LammDLBlumensteinBACrissmanJDMaintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group StudyJ Urol200016341124112910737480
   PubMed Web of Science ®Google Scholar
• SylvesterRJvan derMALammDLIntravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trialsJ Urol200216851964197012394686
   PubMed Web of Science ®Google Scholar
• van der MeijdenAPSylvesterRJOosterlinckWHoeltlWBonoAVMaintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III TrialEur Urol200344442943414499676
   PubMed Web of Science ®Google Scholar
• RawlsWHLammDLLoweBAFatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancerJ Urol19901446132813302231917
   PubMed Web of Science ®Google Scholar
• LammDLBlumensteinBACrawfordEDA randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladderN Engl J Med199132517120512091922207
   PubMed Web of Science ®Google Scholar
• WitjesJAHendricksenKIntravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term resultsEur Urol2008531455217719169
   PubMed Web of Science ®Google Scholar
• NadlerRBCatalonaWJHudsonMARatliffTLDurability of the tumor-free response for intravesical bacillus Calmette-Guerin therapyJ Urol19941522 Pt 13673738015073
   PubMed Web of Science ®Google Scholar
• O’DonnellMAKrohnJDeWolfWCSalvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failedJ Urol2001166413001304 discussion 1304–130511547062
   PubMed Web of Science ®Google Scholar
• JoudiFNSmithBJO’DonnellMAFinal results from a national multicenter Phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancerUrol Oncol200624434434816818189
   PubMed Web of Science ®Google Scholar
• SylvesterRJvan der MeijdenAPWitjesJAKurthKBacillus calmetteguerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trialsJ Urol200517418691 discussion 91–9215947584
   PubMed Web of Science ®Google Scholar
• ShelleyMDCourtJBKynastonHWiltTJColesBMasonMIntravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancerCochrane Database Syst Rev20033CD00323112917955
   PubMedGoogle Scholar
• SylvesterRJOosterlinckWvan der MeijdenAPA single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trialsJ Urol20041716 Pt 121862190 quiz 243515126782
   PubMed Web of Science ®Google Scholar
• SteinbergGBahnsonRBrosmanSMiddletonRWajsmanZWehleMEfficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study GroupJ Urol2000163376176710687972
   PubMed Web of Science ®Google Scholar
• Association of Urogenital Oncology (AUO)Limited vs Extended Lymphadenectomy LEAClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated September 7, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01215071. NLM identifier: NCT01215071Accessed November 19, 2012
   Google Scholar
• S1011: Radical cystectomy for bladder cancer: how many lymph nodes to take?[webpage on the Internet] SWOG (formerly Southwestern Oncology Group)2011 Available from: http://www.swog.org/Visitors/newsletters/2011/08/index.asp?a=s1011Accessed November 19, 2012
   Google Scholar
• SpiessPEKassoufWBrownGImmediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?Urology200667346647116527559
   PubMed Web of Science ®Google Scholar
• RodelCGrabenbauerGGKuhnRCombined-modality treatment and selective organ preservation in invasive bladder cancer: long-term resultsJ Clin Oncol200220143061307112118019
   PubMed Web of Science ®Google Scholar
• ShipleyWUWinterKAKaufmanDSPhase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03J Clin Oncol19981611357635839817278
   PubMed Web of Science ®Google Scholar
• JamesNDHussainSAHallERadiotherapy with or without chemotherapy in muscle-invasive bladder cancerN Engl J Med2012366161477148822512481
   PubMed Web of Science ®Google Scholar
• StenzlACowanNCDe SantisMTreatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelinesEur Urol20115961009101821454009
   PubMed Web of Science ®Google Scholar
• Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaborationEur Urol2005482202205 discussion 205–20615939524
   PubMed Web of Science ®Google Scholar
• von der MaaseHSengelovLRobertsJTLong-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancerJ Clin Oncol200523214602460816034041
   PubMed Web of Science ®Google Scholar
• von der MaaseHHansenSWRobertsJTGemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III studyJ Clin Oncol200018173068307711001674
   PubMed Web of Science ®Google Scholar
• Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis CollaborationEur Urol2005482189199 discussion 199–20115939530
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol200927223584359019487381
   PubMed Web of Science ®Google Scholar
• BellmuntJGonzalez-LarribaJLPriorCPhase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activityAnn Oncol201122122646265321427062
   PubMed Web of Science ®Google Scholar
• GallagherDJMilowskyMIGerstSRPhase II study of sunitinib in patients with metastatic urothelial cancerJ Clin Oncol20102881373137920142593
   PubMed Web of Science ®Google Scholar
• SridharSSWinquistEEisenAA phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II ConsortiumInvest New Drugs20112951045104920191303
   PubMed Web of Science ®Google Scholar
• DreicerRLiHSteinMPhase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology GroupCancer2009115184090409519536901
   PubMed Web of Science ®Google Scholar
• LiYYangXSuLJFlaigTWPazopanib synergizes with docetaxel in the treatment of bladder cancer cellsUrology2011781233. e7e1321529900
   PubMed Web of Science ®Google Scholar
• NecchiAMarianiLZaffaroniNPazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trialLancet Oncol201213881081622819172
   PubMed Web of Science ®Google Scholar
• LamontFRTomlinsonDCCooperPAShnyderSDChesterJDKnowlesMASmall molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivoBr J Cancer20111041758221119661
   PubMed Web of Science ®Google Scholar
• HahnNMStadlerWMZonRTPhase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75J Clin Oncol201129121525153021422406
   PubMed Web of Science ®Google Scholar
• TwardowskiPStadlerWMFrankelPPhase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium TrialUrology201076492392620646741
   PubMed Web of Science ®Google Scholar
• LonnULonnSFribergSNilssonBSilfverswardCStenkvistBPrognostic value of amplification of c-erb-B2 in bladder carcinomaClin Cancer Res1995110118911949815911
   PubMed Web of Science ®Google Scholar
• JimenezREHussainMBiancoFJJrHer-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumorsClin Cancer Res2001782440244711489824
   PubMed Web of Science ®Google Scholar
• WulfingCMachielsJPRichelDJA single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinomaCancer2009115132881289019399906
   PubMed Web of Science ®Google Scholar
• SalzbergMBornerMBauerJAMorantRRauchDRochlitzCTrastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patientsEur J Cancer200642152660266116934972
   PubMed Web of Science ®Google Scholar
• PeyromaureMScotteFAmsellem-OuazanaDVieillefondAOudardSBeuzebocPTrastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patientsEur Urol2005485771775 discussion 775–77816126330
   PubMed Web of Science ®Google Scholar
• HussainMHMacVicarGRPetrylakDPTrastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trialJ Clin Oncol200725162218222417538166
   PubMed Web of Science ®Google Scholar
• ChengJHuangHZhangZTOverexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growthCancer Res200262144157416312124355
   PubMed Web of Science ®Google Scholar
• NealDEMarshCBennettMKEpidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumoursLancet1985184253663682857420
   PubMed Web of Science ®Google Scholar
• WongYNLitwinSVaughnDPhase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinomaJ Clin Oncol201230283545355122927525
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• TickooSKMilowskyMIDharNHypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implicationsBJU Int2011107584484920707797
   PubMed Web of Science ®Google Scholar
• MansureJJNassimRChevalierSRochaJScarlataEKassoufWInhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancerCancer Biol Ther20098242339234720061787
   PubMed Web of Science ®Google Scholar
• SerontERotteySSautoisBPhase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkersAnn Oncol201223102663267022473592
   PubMed Web of Science ®Google Scholar
• MilowskyMIRegazziAMGarcia-GrossmanIRFinal results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urotheliumJ Clin Oncol201129Suppl Abstr 4606
   Google Scholar
• GerullisHEimerCEckeTHA phase II trial of temsirolimus in second-line metastatic urothelial cancerMed Oncol20122942870287622447503
   PubMed Web of Science ®Google Scholar
• JuanpereNAgellLLorenzoMMutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancerHum Pathol201243101573158222417847
   PubMed Web of Science ®Google Scholar
• CourtneyKDCorcoranRBEngelmanJAThe PI3K pathway as drug target in human cancerJ Clin Oncol20102861075108320085938
   PubMed Web of Science ®Google Scholar
• MolinsJBWernerLGuixMPI3KCA mutations in advanced urothelial carcinoma: a potential therapeutic target?201230Suppl 15 Abstr 4582
   Google Scholar
• SharmaPGnjaticSJungbluthAAFrequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancerCancer Immun200331914680360
   PubMedGoogle Scholar
• SharmaPBajorinDFJungbluthAAHerrHOldLJGnjaticSImmune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSFJ Immunother200831984985718833002
   PubMed Web of Science ®Google Scholar
• ZhangPWangJWangDDendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancerInt Immunopharmacol201214325226022884511
   PubMed Web of Science ®Google Scholar
• SwanaHSGrossmanDAnthonyJNWeissRMAltieriDCTumor content of the antiapoptosis molecule survivin and recurrence of bladder cancerN Engl J Med1999341645245310438269
   PubMed Web of Science ®Google Scholar
• KitamuraHTorigoeTHonmaIExpression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapyUrology200667595595916635519
   PubMed Web of Science ®Google Scholar
• HirohashiYTorigoeTMaedaAAn HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivinClin Cancer Res2002861731173912060610
   PubMed Web of Science ®Google Scholar
• HonmaIKitamuraHTorigoeTPhase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancerCancer Immunol Immunother200958111801180719294381
   PubMed Web of Science ®Google Scholar
• CarthonBCWolchokJDYuanJPreoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trialClin Cancer Res201016102861287120460488
   PubMed Web of Science ®Google Scholar
• LiakouCIKamatATangDNCTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patientsProc Natl Acad Sci U S A200810539149871499218818309
   PubMed Web of Science ®Google Scholar
• HendricksenKGleasonDYoungJMSafety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancerJ Urol2008180111612018485407
   PubMed Web of Science ®Google Scholar
• HendricksenKCornelEBde ReijkeTMArentsenHCChawlaSWitjesJAPhase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancerJ Urol201218741195119922335860
   PubMed Web of Science ®Google Scholar
• KowalskiMEntwistleJCizeauJA Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patientsDrug Des Devel Ther20104313320
   PubMed Web of Science ®Google Scholar
• BrunnerAPrelogMVerdorferITzankovAMikuzGEnsingerCEpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladderJ Clin Pathol200861330731017586680
   PubMed Web of Science ®Google Scholar
• KowalskiMGuindonJBrazasLA Phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-GuerinJ Urol201218851712171822998907
   PubMed Web of Science ®Google Scholar
• RistimakiANieminenOSaukkonenKHotakainenKNordlingSHaglundCExpression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladderAm J Pathol2001158384985311238034
   PubMed Web of Science ®Google Scholar
• GulecMAkinHYuceHHAdenosine deaminase and xanthine oxidase activities in bladder washing fluid from patients with bladder cancer: a preliminary studyClin Biochem200336319319612726927
   PubMed Web of Science ®Google Scholar